冻干粉 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
== External links == Official website of the Essendon Football Club Official website of the Australian Football League Archived 22 February 2011 at the Wayback Machine 2013 Season scores and results at AFL Tables 2013 Essendon player statistics at AFL Tables
== Contraindications == Oral ketoconazole has various contraindications, such as concomitant use with certain other drugs due to known drug interactions. Other contraindications of oral ketoconazole include liver disease, adrenal insufficiency, and known hypersensitivity to oral ketoconazole.
== Species distribution and evolution == In addition to mammals, NF-κB is found in a number of simple animals as well. These include cnidarians (such as sea anemones, coral and hydra), porifera (sponges), single-celled eukaryotes including Capsaspora owczarzaki and choanoflagellates, and insects (such as moths, mosquitoes and fruitflies). The sequencing of the genomes of the mosquitoes A. aegypti and A. gambiae, and the fruitfly D. melanogaster has allowed comparative genetic and evolutionary studies on NF-κB. In those insect species, activation of NF-κB is triggered by the Toll pathway (which evolved independently in insects and mammals) and by the Imd (immune deficiency) pathway.
Sources: en.wikipedia.org
Recent studies have shown the presence of microplastics in breast milk, often leading to exposures in very young children. While it has already been established that chemicals such as flame retardants and pesticides have been detected in breast milk, knowledge about microplastics is limited in comparison. A 2022 study detected microplastics in 26 of 34 breast milk samples, with particles ranging from 2 to 12μm in size, raising concerns about infant exposure during critical developmental windows. No safe or harmful exposure level for microplastics has been established, and exposure to MNPs during early developmental stages has raised questions about possible developmental effects or other health issues later in life. Additionally, breast pumps and breastmilk storage bags are frequently made of plastic. Freezing liquid in a plastic container and then heating it up (the "freeze-thaw cycle") has been shown to increase the presence of microplastics. Similar results have been seen from heating plastic reusable food containers in a microwave, showing the increased release of MNPs. It is not recommended that frozen breastmilk ever be thawed in a microwave.
Already chief scientist, Van de Graaff joined HVEC full-time in 1960. He worked with colleagues to introduce the industrial core transformer. Focused on scientific hypothesis at the frontier of the field, he championed development of the company's most ambitious accelerator. Theoretical models predicted an "island of stability" of superheavy elements—heavy atoms that would resist rapid radioactive decay despite lying beyond uranium on the periodic table. Van de Graaff believed that stable superheavy elements could provide nuclear fuel for long-distance space missions or enable compact nuclear weapons, making superheavy ion synthesis the top priority for accelerator research. The proposed 20-megavolt Transuranium Accelerator (XTU) pushed HVEC accelerators towards this frontier. HVEC invested more than $4.6 million in two XTU prototypes (equivalent to $44.4 million in 2025). Anticipating that laboratories would compete to acquire machines capable of historic discoveries, leadership adopted a "build first and seek customers later" approach. During the XTU's construction in 1967–68, federal support for basic nuclear physics declined sharply. The Vietnam War and Great Society programs drew resources away from fundamental research. Simultaneously, the discovery of sub-atomic quarks put the high-energy frontier of physics research beyond the reach of Van de Graaff accelerators. By the time the XTU passed preliminary tests the following year, the U.S. Atomic Energy Commission had said it would not fund purchases.
== Governance == The South African Government department most related to the country's logistics sector is the Department of Transport (DoT). In 2023, the DoT released a Roadmap for the Freight Logistics System in South Africa. In the document, the government outlined that while it believed that strategic infrastructure such as rail and ports would remain publicly-owned, as it belongs to the people of South Africa, operating of such infrastructure could be opened up to private investment. Doing so, the government believes, will allow for increased efficiencies and competitiveness. The roadmap serves as a guide for state-owned transit company Transnet to achieve this balance, translating policy commitments into actions that are to be taken by the entity. In 2025, one of the themes of the Department of Transport's budget was facilitating the development of the country's air cargo capacity. Part of a R21.7-billion Airports Company South Africa (ACSA) infrastructure development allocation was set aside for increasing air freight handling through its network of airports. South Africa's fuel pipelines are regulated by the National Energy Regulator of South Africa (NERSA).
Sources: en.wikipedia.org
== Usage as doping product == As a performance-enhancing drug, EPO has been banned since the early 1990s, but a test was not available until the 2000 Summer Olympics. Before this test was available, some athletes were sanctioned after confessing to having used EPO, for example in the Festina affair, when a car with doping products for the Festina cycling team was found. The first doping test in cycling was used in the 2001 La Flèche Wallonne. The first rider to test positive in that race was Bo Hamburger, although he was later acquitted because his B-sample was not conclusive. The U.S. Postal Service Pro Cycling Team, under the leadership of Lance Armstrong and Johan Bruyneel, ran a sophisticated doping program that lasted for many years during the late 1990s and early 2000s. Erythropoietin was a common substance used by the cyclists. Studies of the effectiveness of EPO in cycling consistently associate EPO with an increase in subjects' maximal aerobic capacity, but yield mixed results as to the drug's effects on submaximal aerobic efforts. A 2007 study showed that EPO treatment led to a statistically significant improvement in cyclists' abilities to maintain a "submaximal" effort of about 80% of their pre-treatment aerobic maximum (VO2max). The study found that subjects treated with EPO saw increased VO2max values, and the amount of time they could maintain their initial submaximal effort also increased.
==== Europe ==== In the Netherlands, diamorphine is a List I drug of the Opium Law. It is available for prescription under tight regulation exclusively to long-term addicts for whom methadone maintenance treatment has failed. It cannot be used to treat severe pain or other illnesses. In the United Kingdom, diamorphine is available by prescription, though it is a restricted Class A drug. According to the 50th edition of the British National Formulary (BNF), diamorphine hydrochloride may be used in the treatment of acute pain, myocardial infarction, acute pulmonary oedema, and chronic pain. The treatment of chronic non-malignant pain must be supervised by a specialist. The BNF notes that all opioid analgesics cause dependence and tolerance but that this is "no deterrent in the control of pain in terminal illness". When used in the palliative care of cancer patients, diamorphine is often injected using a syringe driver. In Switzerland, heroin is produced in injectable or tablet form under the brand name Diaphin by a private company under contract to the Swiss government. Swiss-produced heroin has been imported into Canada with government approval.
=== Efficacy === The efficacy of α-bungarotoxin can be assessed by analyzing their binding affinity. It affects how the signal transmits at the skeletal neuromuscular junction by binding to the postsynaptic nAChRs at high affinity. The affinity of the toxin for this receptor is measured with a dissociation constant (Kd), ranging from 10-11 to 10-9 M. In addition to binding to skeletal neuromuscular junctions, it can specifically bind to different neuronal subsets, such as α7. This binding affinity is only slightly lower with Kd measured in the range of 10-9 to 10-8 M. It can also be analyzed through receptor inhibition, specifically inhibiting the action of acetylcholine on nAChRs. One study found that 5 mirograms/ml of the toxin completely blocks the endplate potential and extrajunctional acetylcholine sensitivity of surface fibers, within approximately 35 minutes in normal and chronically denervated muscles. They performed a washout period of 6.5 hours, which resulted in a partial recovery of the endplate potential, with an amplitude of 0.72 +/- 0.033 mV in normal muscles. In denervated muscles, a partial recovery of acetylcholine sensitivity was observed, with an amplitude of 41.02 +/- 3.95 mV/nC compared to a control amplitude of 1215 +/- 197 mV/nC. This same study also found a small population of acetylhcoline receptors (1% of the total population) to react with α-bungarotoxin reversibly. With the toxin, either 20 μM carbamylcholine or decamethonium was used simultaneously in normal muscles.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.